Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shingles shot shows promise in Mid-Stage trial

NCT ID NCT07481604

Prevention Sponsor: CHA Vaccine Institute Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new shingles vaccine in 135 healthy adults aged 50 and older. Researchers will compare the immune response and safety of the new vaccine against an existing one to find the best dose. The goal is to prevent shingles, a painful rash caused by the chickenpox virus.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following criteria: * Healthy adults aged 50 years or older * Able to understand the study procedures and provide written informed consent * Females and males of reproductive potential must agree to use medically acceptable contraception until 3 months after the last vaccination * Females of childbearing potential must have a negative pregnancy test prior to vaccination Exclusion Criteria: * Participants meeting any of the following criteria will be excluded: * History of herpes zoster prior to screening * History of severe allergic reaction to vaccines or vaccine components * Known immunodeficiency or immune dysfunction * Prior vaccination with varicella or herpes zoster vaccine * Use of immunosuppressive therapy or systemic steroids that may affect immune response * Positive test for HCV, HBV, or HIV at screening * Pregnant or breastfeeding women * Any medical condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Herpes zoster are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chickenpox herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Herpes zoster

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea

  • Chung-Ang University Hospital

    Seoul, Seoul, South Korea

  • Ewha Womans University Seoul Hospital

    Seoul, Seoul, South Korea

  • Jeonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, Daegu, South Korea

  • The Catholic University of Korea Eunpyeong St. Mary's Hospital

    Seoul, Seoul, 03312, South Korea

  • Yongin Severance Hospital, Yonsei University Health System

    Yongin, Gyeonggi-do, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.